Advances in mechanism of immunomodulatory drug resistance in multiple myeloma
10.3760/cma.j.issn.1009-9921.2018.11.016
- VernacularTitle:多发性骨髓瘤对免疫调节剂耐药机制的研究进展
- Author:
Wensi QIAN
1
,
2
;
Yanhui XIE
Author Information
1. 200040 上海,复旦大学上海医学院
2. 200040 上海,复旦大学附属华东医院血液内科
- Keywords:
Multiple myeloma;
Immunomodulatory drugs;
Cereblon;
Drug resistance
- From:
Journal of Leukemia & Lymphoma
2018;27(11):697-700
- CountryChina
- Language:Chinese
-
Abstract:
The use of immunomodulators represented by thalidomide and its derivatives in the treatment of multiple myeloma (MM) has made a breakthrough. Cereblon has been identified as a direct target for immunomodulators and plays a significant role in antiproliferation, proapoptotic effects, antiangiogenic activities, enhancement of the activity of T cells and NK cells and intervention of cell surface adhesion molecules between myeloma cells and bone marrow stromal cells. In recent years, majority of the MM patients treated with immunomodulators develop drug resistance. Both upstream and downstream factor expression of cereblon and epigenetic modification may be related to immunomodulatory drugs resistance in MM. This review discusses the mechanism of immunomodulatory drug resistance in MM.
